Matthew Sample, MD
Cardiovascular Disease · Birmingham, ALNPI 1871736637
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 64.6% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2020 at $5,798 and has fallen 59.8% since, to $2,331 in 2025.
Across 169 payments — averaging $99.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$11K
- Edwards Lifesciences$2K
- Medtronic$665
- Inari Medical, Inc.$623
- Philips North America LLC$530
- Shockwave Medical, Inc$393
- plus $1K from 17 others
Across 34 payments — averaging $1430.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Stryker$33K
- Inari Medical, Inc.$16K
What the payments were for
- Speaking & faculty fees$4,65028%
- Travel & lodging$3,37220%
- Food & beverage$8,75452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 61 | $10,843 |
| Edwards Lifesciences | 35 | $2,259 |
| Medtronic | 9 | $665 |
| Inari Medical, Inc. | 12 | $623 |
| Philips North America LLC | 10 | $530 |
| Shockwave Medical, Inc | 2 | $393 |
| Boston Scientific | 3 | $321 |
| W. L. Gore & Associates, Inc. | 3 | $254 |
| Cvrx, Inc. | 3 | $183 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $145 |
| Angiodynamics, Inc. | 1 | $94 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $86 |
| Celonova Biosciences, Inc. | 1 | $66 |
| Terumo Medical Corporation | 1 | $62 |
| Siemens Medical Solutions USA, Inc. | 3 | $49 |
| Cardiva Medical, Inc. | 2 | $39 |
| GE HealthCare | 2 | $32 |
| Stryker | 1 | $30 |
| Atricure, Inc. | 1 | $26 |
| Novartis | 1 | $23 |
| Livanova USA, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mitra Clip system$5,709
- MitraClip$1,468
- TRICLIP$511
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$393
- AMPLATZER$385
- SAPIEN 3 Ultra RESILIA$372
- Edwards SAPIEN 3 Transcatheter Heart Valve$279
- FLOWTRIEVER CATHETER, S$232
- RESOLUTE ONYX$164
- Abre$163
- ONYX FRONTIER$150
- PASCAL$143
- NAVITOR$134
- AMPLATZER Occluders$132
- GORE CARDIOFORM Septal Occluder$121
- AMPLATZER AMULET$105
- Barostim Neo System$103
How this compares
$16,776 in reported general payments places this provider in the 85th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 458 | $421,720 |
| EntrestoSacubitril/Valsartan | 215 | $199,560 |
| CamzyosMavacamten | 12 | $98,386 |
| XareltoRivaroxaban | 101 | $93,137 |
| FarxigaDapagliflozin Propanediol | 41 | $47,254 |
| JardianceEmpagliflozin | 28 | $19,516 |
| Repatha SureclickEvolocumab | 21 | $17,886 |
| Atorvastatin Calcium | 562 | $9,956 |
| VascepaIcosapent Ethyl | 16 | $9,707 |
| Metoprolol Succinate | 478 | $8,806 |
| Ezetimibe | 126 | $5,206 |
| Rosuvastatin Calcium | 214 | $5,077 |
| Chlorthalidone | 235 | $4,951 |
| ClopidogrelClopidogrel Bisulfate | 277 | $3,645 |
| Carvedilol | 285 | $3,463 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $23 | $199,560215 claims |
| Johnson & JohnsonXarelto | $14 | $93,137101 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Birmingham
- Vikram AroraBirmingham$271K
- Jason ThompsonBirmingham$248K
- Michael WilenskyBirmingham$241K
- Mustafa AhmedBirmingham$218K
- Frederick GaskinBirmingham$115K
- Pankaj AroraBirmingham$83K
- Thomas CawthonBirmingham$54K
- Weihan ChenBirmingham$51K
- Farrell MendelsohnBirmingham$51K
- Charles MooreBirmingham$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.